How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,238 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer

the severity of diarrhea after 1 week of treatment in patients with MTC. Secondary Outcome Measures : Functional impact of CASAD [ Time Frame: 1 week ] To explore the functional impact of CASAD and the relative impact of diarrhea in relation to other symptom issues using MDASI-THY (M.D. Anderson Symptom Inventory-Thyroid, appendix D) Effect on thyroid function tests [ Time Frame: 1 week ] To explore the effect of CASAD on thyroid function tests, thyroid hormone and calcium absorption Changes in MDASI-THY (...) The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2012 Clinical Trials

142. Lactobacillus Preparation on the Incidence of Diarrhea

of probiotics till the day of 1st diarrhea. If patients are transferred to ward, this study ends in each patient. Secondary Outcome Measures : 28day-mortality [ Time Frame: 28 day ] Mortality in 28th day of ICU residence Positive results of C.difficile toxin [ Time Frame: The first onset of diarrhea during ICU residence (up to 8 weeks) ] If diarrhea (>600ml/day) occurs during ICU residence, we will perform C.difficile toxin assays to determine the cause of diarrhea. ICU-acquired pneumonia [ Time Frame (...) Lactobacillus Preparation on the Incidence of Diarrhea Lactobacillus Preparation on the Incidence of Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Lactobacillus Preparation on the Incidence

2012 Clinical Trials

143. Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea

to Prevent ETEC Diarrhea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01644565 Recruitment Status : Unknown Verified October 2015 by U.S. Army Medical Research and Materiel Command. Recruitment status was: Active, not recruiting First Posted : July 19, 2012 Last Update Posted : November 2, 2015 Sponsor (...) Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety Study of Chimeric Vaccine

2012 Clinical Trials

144. Probiotic Supplementation in Preventing Treatment-Related Diarrhea in Patients With Cancer Undergoing Chemotherapy

/severe (grade 2-4) diarrhea graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. II. Functional Assessment of Chronic Illness Therapy - Diarrhea (FACIT-D) Trial Outcome Index. SECONDARY OBJECTIVES: I. To evaluate the effects of probiotic supplementation on dose delays or reductions due to gastrointestinal (GI) toxicity. II. To evaluate the effects of probiotic supplementation on anti-diarrheal medication use. III. To evaluate the effects of probiotic supplementation (...) and conventional cytotoxic chemotherapy will be analyzed both combined and separately. FACIT-D Trial Outcome Index (TOI) [ Time Frame: Up to 4 weeks post treatment ] The FACIT-D TOI has a range of scores from 0-100 which are a combination of physical well being, functional well being, and diarrhea subscale. The data for patients on tyrosine kinase inhibitors and conventional cytotoxic chemotherapy will be analyzed both combined and separately. Secondary Outcome Measures : Dose delays or reductions due to GI

2012 Clinical Trials

145. Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea

to Prevent ETEC Diarrhea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01382095 Recruitment Status : Completed First Posted : June 27, 2011 Last Update Posted : April 27, 2015 Sponsor: U.S. Army Medical Research and Materiel Command Information provided by (Responsible Party): U.S. Army Medical Research (...) Reed Army Institute of Research ) First Posted: June 27, 2011 Last Update Posted: April 27, 2015 Last Verified: April 2015 Keywords provided by U.S. Army Medical Research and Materiel Command: ETEC Diarrhea Vaccine Additional relevant MeSH terms: Layout table for MeSH terms Escherichia coli Infections Enterobacteriaceae Infections Gram-Negative Bacterial Infections Bacterial Infections

2011 Clinical Trials

146. Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)

Patients who drink over 2oz alcohol/day on a regular basis Any other causes for diarrhea such as IBD, microscopic colitis, celiac disease, history of abdominal obstruction, pancreatitis, ileus, or any gastrointestinal bleeding. Patients with active malignancy in the past five years Patient with any history of hypersensitivity reactions to salicylate containing medications due to cross-sensitivity with mesalamine or allergy to mesalamine medications in the past Any subjects with fibromyalgia (...) Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS) Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2011 Clinical Trials

147. Bioequivalence Between a Racecadotril Capsule and Film-Coated Tablet (FCT) to Treat Diarrhea in Adults

Bioequivalence Between a Racecadotril Capsule and Film-Coated Tablet (FCT) to Treat Diarrhea in Adults Bioequivalence Between a Racecadotril Capsule and Film-Coated Tablet (FCT) to Treat Diarrhea in Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Bioequivalence Between a Racecadotril Capsule and Film-Coated Tablet (FCT) to Treat Diarrhea in Adults The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01302093 Recruitment Status : Completed First Posted : February 23, 2011 Last Update Posted : July 10

2011 Clinical Trials

148. Zinc Supplementation and Severe and Recurrent Diarrhea

Diarrhea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01306097 Recruitment Status : Completed First Posted : March 1, 2011 Last Update Posted : March 1, 2011 Sponsor: Hormozgan University of Medical Sciences Information provided by: Hormozgan University of Medical Sciences Study Details Study (...) : 1 years ] Incidence, Duration and frequency Secondary Outcome Measures : Admission for diarrhea [ Time Frame: 1 year ] Total number of admissions during the study period Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using

2011 Clinical Trials

149. Early Administration of Lactose-free Milk in Children Presenting With Acute Diarrhea

adding more. Early Administration of Lactose-free Milk in Children Presenting With Acute Diarrhea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01269892 Recruitment Status : Completed First Posted : January 4, 2011 Last Update Posted : January 4, 2011 Sponsor: Isfahan University of Medical Sciences (...) Information provided by: Isfahan University of Medical Sciences Study Details Study Description Go to Brief Summary: The purpose of this study is to determine which nutritional regime is better for acute diarrhea in outcomes. Condition or disease Intervention/treatment Phase Acute Diarrhea Dietary Supplement: lactose-free milk Dietary Supplement: conventional milk Phase 2 Detailed Description: Diarrhea is still the most important cause of mortality and morbidity in children of the developing countries. We

2011 Clinical Trials

150. Effect of Herbal Extract Granules Combined With Probiotics on Irritable Bowel Syndrome With Diarrhea

Sponsor: Kyunghee University Medical Center Information provided by (Responsible Party): Seok-Jae Ko, Kyunghee University Medical Center Study Details Study Description Go to Brief Summary: The aims of this study are to investigate the effect of famous herbal formula extract and probiotics on irritable bowel syndrome with diarrhea, and to determine whether these two experimental items affect intestinal permeability and the composition of intestinal microbiota. Condition or disease Intervention (...) : June 5, 2012 Last Verified: June 2012 Keywords provided by Seok-Jae Ko, Kyunghee University Medical Center: Irritable bowel syndrome Herbal medicine Probiotics Additional relevant MeSH terms: Layout table for MeSH terms Syndrome Diarrhea Irritable Bowel Syndrome Disease Pathologic Processes Signs and Symptoms, Digestive Signs and Symptoms Colonic Diseases, Functional Colonic Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases

2011 Clinical Trials

151. Prevention of Irinotecan Induced Diarrhea by Probiotics

cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle. Outcome Measures Go to Primary Outcome Measures : Prevention of grade 3-4 diarrhea by probiotics in patients treated by irinotecan based chemotherapy [ Time Frame: 2 years ] Secondary Outcome Measures : Prevention of any grade of diarrhea [ Time Frame: 2 years ] Number of patients with any grade 3 or 4 toxicity or SAE related toxicity. [ Time Frame: 2 years ] Number of patients (...) Prevention of Irinotecan Induced Diarrhea by Probiotics Prevention of Irinotecan Induced Diarrhea by Probiotics - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Prevention of Irinotecan Induced Diarrhea

2011 Clinical Trials

152. Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children

in patients ingesting L. reuteri versus placebo during the study period, measured as mean number of episodes per patient. An episode of diarrhea is defined as three or more (≥ 3) soft and unformed or watery bowel movements per day for at least 48 hours. Secondary Outcome Measures : Incidence of mild diarrhea and severity if diarrhea in children with probiotic treatment [ Time Frame: 2 years ] Incidence of mild diarrhoea during and after treatment with antibiotics in patients ingesting L. reuteri versus (...) Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

2011 Clinical Trials

153. Cost-effectiveness of Infloran (TM) in Treating Acute Childhood Diarrhea in Phramongkutklao Hospital

Cost-effectiveness of Infloran (TM) in Treating Acute Childhood Diarrhea in Phramongkutklao Hospital Cost-effectiveness of Infloran (TM) in Treating Acute Childhood Diarrhea in Phramongkutklao Hospital - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Cost-effectiveness of Infloran (TM) in Treating Acute Childhood Diarrhea in Phramongkutklao Hospital (infloran) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01273012 Recruitment Status : Unknown Verified July 2011 by Phramongkutklao College of Medicine

2011 Clinical Trials

154. Influence of Carob and Probiotics on Acute Diarrhea in Children

and Probiotics on Acute Diarrhea in Children The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01501305 Recruitment Status : Unknown Verified December 2011 by Hillel Yaffe Medical Center. Recruitment status was: Not yet recruiting First Posted : December 29, 2011 Last Update Posted : December 29, 2011 Sponsor (...) : Hillel Yaffe Medical Center Information provided by (Responsible Party): Hillel Yaffe Medical Center Study Details Study Description Go to Brief Summary: Comparison of Carob powder with probiotics vs oral hydration solution in diarrhea treatment in children. Condition or disease Intervention/treatment Phase Diarrhea Dietary Supplement: Mineral solution Dietary Supplement: Carob powder with probiotics Phase 1 Phase 2 Study Design Go to Layout table for study information Study Type : Interventional

2011 Clinical Trials

155. A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01494233

2011 Clinical Trials

156. The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers

will be allowed during the study Receipt of influenza vaccination will be allowed prior, during, and/or after the study Use of topical medications that are not significantly absorbed systemically will be allowed if approved by the Principal Investigator Inability to obtain venous access for sample collection. Inability to swallow whole capsules and/or tablets. Positive serum or urine pregnancy test or breastfeeding female. The presence of persistent diarrhea or malabsorption that could interferewith (...) The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2013 Clinical Trials

157. Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease

have shown that sexual function is impaired in patients with Crohn's disease. It is likely that both the symptoms related to the disease, medications used to treat the disease, and surgery all impair sexual function in a variety of ways. For example, body image may be impaired, patients may be worried about bowel incontinence or unpleasant odors associated with diarrhea, patients may have significant pelvic pain secondary to perianal fistulas, or they may have painful intercourse from adjacent (...) : Vanderbilt University Milton S. Hershey Medical Center Mercy Medical Center Information provided by (Responsible Party): Raymond Cross, University of Maryland Study Details Study Description Go to Brief Summary: Crohn's disease is a chronic inflammatory condition of the intestines that causes abdominal pain, diarrhea, tunnels around the anus (fistulas), and extraintestinal symptoms. Effective medical treatments exist to treat the disease; however they can have significant side effects. Previous studies

2015 Clinical Trials

158. Effect of Early Nutritional Therapy on Frailty, Functional Outcomes and Recovery of Undernourished Medical Inpatients Trial

decline. The primary composite endpoint is combined adverse outcome within 30 days defined as (a) all-cause mortality, (b) admission to the intensive care unit from the medical ward, (c) major complications, (d) unplanned hospital readmissions and (d) decline in functional outcome from admission to day 30 assessed by Barthel`s index (-10%). Secondary endpoints include (a) each single component of the primary endpoint (b) short-term nutritional and functional outcomes from inclusion to day 10 (...) of baseline creatinine or new requirement of dialysis), gastro-intestinal hemorrhage or intestinal perforation assessed by medical chart review and telephone interview decline in functional status of 10% or more from admission to day 30 measured by the Barthel`s index assessed by patient interview on admission and after 30 days Secondary Outcome Measures : Weight change [ Time Frame: measured at day 30 by telephone interview ] change in weight and BMI from inclusion to day 30 by patient interview

2015 Clinical Trials

159. Surgery Versus Best Medical Management for the Long Term Remission of Type 2 Diabetes and Related Diseases (REMISSION)

with Duodenal Switch Active Comparator: Control the best medical management of their diabetes, non-surgical group Other: Medical management Outcome Measures Go to Primary Outcome Measures : Type 2 diabetes remission rate [ Time Frame: from baseline up to 60 months ] percent of patient achieving type 2 diabetes remission in each groups Secondary Outcome Measures : Change in microalbuminuria [ Time Frame: from baseline up to 60 months ] Normalisation of A/C ratio after surgery Change in retinopathy [ Time (...) Surgery Versus Best Medical Management for the Long Term Remission of Type 2 Diabetes and Related Diseases (REMISSION) Surgery Versus Best Medical Management for the Long Term Remission of Type 2 Diabetes and Related Diseases (REMISSION) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2015 Clinical Trials

160. Determining the Responsiveness of Depression Questionnaires and Optimal Treatment Duration for Antidepressant Medications

Determining the Responsiveness of Depression Questionnaires and Optimal Treatment Duration for Antidepressant Medications Evidence-based Synthesis Program Department of Veterans Affairs Health Services Research & Development Service Evidence-based Synthesis Program Evidence Synthesis for Determining the Responsiveness of Depression Questionnaires and Optimal Treatment Duration for Antidepressant Medications Department of Veterans Affairs Health Services Research & Development Service October (...) 2009 Investigators: John W. Williams Jr., MD, MHS Professor of Medicine and Psychiatry, Durham VA Medical Center and Duke University Director, Evidence-Based Practice Center Durham, NC Monica Nora Slubicki, MD Resident in Psychiatry, VA Administrative Chief Resident 2009-2010, Duke University Medical Center Durham, NC Damon S. Tweedy, MD Medical Director, Primary-Care Mental Health Integration, Durham VA Medical Center Consulting Associate, Duke University Medical Center Durham, NC Prepared

2009 Veterans Affairs Evidence-based Synthesis Program Reports

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>